MetaCap

Cingulate (CING) vs Polaryx Therapeutics (PLYX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Cingulate is the larger company by market cap ($67.5 million vs $66.3 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CING-26.19%PLYX-96.20%
+100%-3%-106%
Feb 2, 20261 yearNov 20, 2026
CING-41.43%PLYX-85.07%
+18%-36%-90%
Feb 2, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CING versus PLYX key metrics
MetricCINGPLYX
Share price$4.51$1.33
Market cap$67.48M$66.30M
1-day change-14.26%-11.92%
YTD return+3.92%—
1-year return+27.76%—
EPS (TTM)$-2.67$-0.18
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-22.45M$-8.98M
52-week high$11.89$48.91
52-week low$3.16$1.30
Distance from 52-week high-62.07%-97.28%
Analyst consensusnonenone
Avg. price target upside+370.07%+463.91%
Average volume178.82K36.42K
Shares outstanding14.96M49.85M
Employees142
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Cingulate

CING stock →

Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults.

Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees

About Polaryx Therapeutics

PLYX stock →

Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage novel gene therapy candidate.

Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees

CING vs PLYX FAQ

Which is bigger, Cingulate or Polaryx Therapeutics?

Cingulate (CING) is larger, with a market capitalization of $67.48M compared with $66.30M for Polaryx Therapeutics (PLYX).

Are Cingulate and Polaryx Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons